Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- opicapone
- solriamfetol
Interactions between your drugs
opicapone solriamfetol
Applies to: opicapone, solriamfetol
MONITOR: Coadministration of solriamfetol with other drugs that increase dopamine levels or that bind directly to dopamine receptors may increase the risk of dopaminergic-related adverse effects. The mechanism of the interaction has not been reported, but it may involve synergistic or additive central dopaminergic effects. This interaction has not been evaluated clinically.
MANAGEMENT: Caution is advised if solriamfetol is administered concomitantly with other dopaminergic drugs. Dosage adjustments and close patient monitoring should be considered whenever solriamfetol is used with other dopaminergic drugs.
References (1)
- (2019) "Product Information. Sunosi (solriamfetol)." Jazz Pharmaceuticals
Drug and food interactions
opicapone food
Applies to: opicapone
ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of opicapone. When opicapone was administered following a moderate fat/moderate calorie meal, mean opicapone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 62% and 31%, respectively, while the time to reach peak concentration (Tmax) was delayed by 4 hours.
MANAGEMENT: Patients should avoid eating 1 to 2 hours before and after taking opicapone.
References (2)
- Cerner Multum, Inc. "Australian Product Information."
- (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Sinemet
Sinemet is used to treat symptoms of Parkinson's disease, such as muscle stiffness, tremors ...
Cogentin
Cogentin is used for extrapyramidal reaction, parkinson's disease
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Requip
Requip is used to treat symptoms of Parkinson's disease, such as stiffness, tremors and muscle ...
Mirapex
Mirapex (pramipexole) treats the symptoms of Parkinson's disease and is also used to treat Restless ...
Rytary
Rytary is used to treat symptoms of Parkinson's disease and parkinsonism that may follow carbon ...
Azilect
Azilect (rasagiline) is used to treat the symptoms of Parkinson's disease. Learn about side ...
Crexont
Crexont (carbidopa and levodopa) is an extended-release capsule that may be used to treat symptoms ...
Exelon
Exelon (rivastigmine) is used to treat dementia caused by Alzheimer's or Parkinson's disease ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.